Communications Biology (Feb 2022)
An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis
- Kiel Hards,
- Chen-Yi Cheung,
- Natalie Waller,
- Cara Adolph,
- Laura Keighley,
- Zhi Shean Tee,
- Liam K. Harold,
- Ayana Menorca,
- Richard S. Bujaroski,
- Benjamin J. Buckley,
- Joel D. A. Tyndall,
- Matthew B. McNeil,
- Kyu Y. Rhee,
- Helen K. Opel-Reading,
- Kurt Krause,
- Laura Preiss,
- Julian D. Langer,
- Thomas Meier,
- Erik J. Hasenoehrl,
- Michael Berney,
- Michael J. Kelso,
- Gregory M. Cook
Affiliations
- Kiel Hards
- Department of Microbiology and Immunology, University of Otago
- Chen-Yi Cheung
- Department of Microbiology and Immunology, University of Otago
- Natalie Waller
- Department of Microbiology and Immunology, University of Otago
- Cara Adolph
- Department of Microbiology and Immunology, University of Otago
- Laura Keighley
- Department of Microbiology and Immunology, University of Otago
- Zhi Shean Tee
- Department of Microbiology and Immunology, University of Otago
- Liam K. Harold
- Department of Microbiology and Immunology, University of Otago
- Ayana Menorca
- Department of Microbiology and Immunology, University of Otago
- Richard S. Bujaroski
- Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong
- Benjamin J. Buckley
- Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong
- Joel D. A. Tyndall
- School of Pharmacy, University of Otago
- Matthew B. McNeil
- Department of Microbiology and Immunology, University of Otago
- Kyu Y. Rhee
- Weill Department of Medicine, Weill Cornell Medical College
- Helen K. Opel-Reading
- Department of Biochemistry, University of Otago
- Kurt Krause
- Maurice Wilkins Centre for Molecular Biodiscovery, The University of Otago
- Laura Preiss
- Department of Structural Biology, Max-Planck Institute of Biophysics
- Julian D. Langer
- Department of Molecular Membrane Biology, Max-Planck Institute of Biophysics
- Thomas Meier
- Department of Life Sciences, Imperial College London
- Erik J. Hasenoehrl
- Department of Microbiology and Immunology, Albert Einstein College of Medicine
- Michael Berney
- Department of Microbiology and Immunology, Albert Einstein College of Medicine
- Michael J. Kelso
- Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong
- Gregory M. Cook
- Department of Microbiology and Immunology, University of Otago
- DOI
- https://doi.org/10.1038/s42003-022-03110-8
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 11
Abstract
Derivatives of the FDA-approved drug, amiloride, can eliminate drug-resistant Mycobacterium tuberculosis in vitro by interfering with bacterial energy conservation.
